Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo
nivolumab · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adjuvant therapy after complete resection of esophageal or gastroesophageal junction cancer with residual pathologic disease after neoadjuvant chemoradiotherapy.
LAMPGEN ANALYSIS
Why it matters
Residual disease after multimodality treatment defines this postoperative indication.
What research teams should watch
Reconcile preoperative chemoradiation, margin status, residual disease and surgery date.
PRIMARY RECORDS